Research progress in neoadjuvant therapy for pancreatic neuroendocrine neoplasms

doi:10.3877/cma.j.issn.2095-3232.2024.04.007

Abstract

Abstract:

Pancreatic neuroendocrine neoplasms (pNENs) is a category of highly heterogeneous tumors. Surgery is the only treatment option that offers the potential to cure pNENs. Neoadjuvant therapy enables patients with locally advanced pNENs or liver metastases to obtain the chance of reoperation. Neoadjuvant therapies for pNENs mainly include chemotherapy, targeted therapy, somatostatin analogues, and peptide receptor-radionuclide therapy, etc. CAPTEM regimen and platinum-based chemotherapy regimen are commonly used in chemotherapy. Somatostatin analogues and peptide receptor-radionuclide therapy are primarily given for individuals with high expression of somatostatin receptor. Targeted therapy is mainly delivered for locally advanced well-differentiated pNENs. These regimens can be adopted alone or combined to enhance clinical efficacy. At present, high-level evidence-based medicine evidence is lacking in the selection of treatment regimens, and systematic evaluation is also lacking in comparison of the clinical efficacy among different protocols.

Key words: Pancreatic neuroendocrine neoplasms, Neoadjuvant therapy, Chemotherapy, Targeted therapy, Somatostatin analogues, Peptide receptor-radionuclide therapy

Yongzheng Li, Yufan Meng, Zhiyao Fan, Hanxiang Zhan. Research progress in neoadjuvant therapy for pancreatic neuroendocrine neoplasms[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(04): 481-486.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3232.2024.04.007

https://zhgzwkssxdzzz.cma-cmc.com.cn/EN/Y2024/V13/I04/481

References 39

[1]	Cives M, Strosberg JR. Gastroenteropancreatic neuroendocrine tumors[J]. CA Cancer J Clin, 2018, 68(6):471-487.
[2]	Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States[J]. JAMA Oncol, 2017, 3(10):1335-1342.
[3]	Jensen RT, Bodei L, Capdevila J, et al. Unmet needs in functional and nonfunctional pancreatic neuroendocrine neoplasms[J]. Neuroendocrinology, 2019, 108(1):26-36.
[4]	Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system[J]. Histopathology, 2020, 76(2):182-188.
[5]	Shi M, Fan Z, Xu J, et al. Gastroenteropancreatic neuroendocrine neoplasms G3: novel insights and unmet needs[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876(2):188637.
[6]	吴文铭, 陈洁, 白春梅, 等. 中国胰腺神经内分泌肿瘤诊疗指南(2020)[J]. 中国实用外科杂志, 2021, 41(6):601-617, 632.
[7]	王文权, 楼文晖, 刘亮. 胰腺神经内分泌肿瘤热点问题的思考[J]. 中华消化外科杂志, 2022, 21(8):1031-1037.
[8]	Ma ZY, Gong YF, Zhuang HK, et al. Pancreatic neuroendocrine tumors: a review of serum biomarkers, staging, and management[J]. World J Gastroenterol, 2020, 26(19):2305-2322.
[9]	Memeh KO, Vaghaiwalla T, Keutgen XM. Surgical treatment of non-functioning pancreatic neuroendocrine tumors: current controversies and challenges[J]. Journal of Pancreatology, 2020, 3(2):51-58.
[10]	Cloyd JM, Omichi K, Mizuno T, et al. Preoperative fluorouracil, doxorubicin, and streptozocin for the treatment of pancreatic neuroendocrine liver metastases[J]. Ann Surg Oncol, 2018, 25(6):1709-1715.
[11]	Garcia-Carbonero R, Sorbye H, Baudin E, et al. ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas[J]. Neuroendocrinology, 2016, 103(2):186-194.
[12]	Li Y, Fan Z, Zhang F, et al. Neoadjuvant therapy in pancreatic neuroendocrine neoplasms: a systematic review and meta-analysis[J]. Front Oncol, 2022, 12: 981575.
[13]	Palmieri LJ, Dermine S, Barré A, et al. Medical treatment of advanced pancreatic neuroendocrine neoplasms[J]. J Clin Med, 2020, 9(6):1860.
[14]	Cives M, Strosberg J. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors[J]. Drugs, 2015, 75(8):847-858.
[15]	Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors[J]. N Engl J Med, 2014, 371(3):224-233.
[16]	Raymond E, Hammel P, Dreyer C, et al. Sunitinib in pancreatic neuroendocrine tumors[J]. Target Oncol, 2012, 7(2):117-125.
[17]	Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors[J]. N Engl J Med, 2011, 364(6):501-513.
[18]	Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors[J]. N Engl J Med, 2011, 364(6):514-523.
[19]	Mpilla GB, Uddin MH, Al-Hallak MN, et al. PAK4-NAMPT dual inhibition sensitizes pancreatic neuroendocrine tumors to everolimus[J]. Mol Cancer Ther, 2021, 20(10):1836-1845.
[20]	Vitali E, Boemi I, Tarantola G, et al. Metformin and everolimus: a promising combination for neuroendocrine tumors treatment[J]. Cancers, 2020, 12(8):2143.
[21]	Kurita Y, Kobayashi N, Hara K, et al. Effectiveness and prognostic factors of everolimus in patients with pancreatic neuroendocrine neoplasms[J]. Intern Med, 2023, 62(2):159-167.
[22]	Daskalakis K, Tsoli M, Angelousi A, et al. Anti-tumour activity of everolimus and sunitinib in neuroendocrine neoplasms[J]. Endocr Connect, 2019, 8(6):641-653.
[23]	Walter MA, Nesti C, Spanjol M, et al. Treatment for gastrointestinal and pancreatic neuroendocrine tumours: a network meta-analysis[J]. Cochrane Database Syst Rev, 2021, 11(11):CD013700.
[24]	Murase Y, Kudo A, Akahoshi K, et al. Surgery after sunitinib administration to improve survival of patients with advanced pancreatic neuroendocrine neoplasms[J]. Ann Gastroenterol Surg, 2021, 5(5):692-700.
[25]	Das S, Al-Toubah T, Strosberg J. Chemotherapy in neuroendocrine tumors[J]. Cancers, 2021, 13(19):4872.
[26]	Pavel M, Öberg K, Falconi M, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2020, 31(7):844-860.
[27]	Morizane C, Machida N, Honma Y, et al. Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: the TOPIC-NEC phase 3 randomized clinical trial[J]. JAMA Oncol, 2022, 8(10):1447-1455.
[28]	Li K, Yuan J, Li Y, et al. Successful neoadjuvant chemotherapy for small-cell neuroendocrine carcinoma of the pancreas: a case report[J]. Front Oncol, 2021, 11:719422.
[29]	Spada F, Antonuzzo L, Marconcini R, et al. Oxaliplatin-based chemotherapy in advanced neuroendocrine tumors: clinical outcomes and preliminary correlation with biological factors[J]. Neuroendocrinology, 2016, 103(6):806-814.
[30]	Rogers JE, Lam M, Halperin DM, et al. Fluorouracil, doxorubicin with streptozocin and subsequent therapies in pancreatic neuroendocrine tumors[J]. Neuroendocrinology, 2022, 112(1):34-42.
[31]	Prakash L, Bhosale P, Cloyd J, et al. Role of fluorouracil, doxorubicin, and streptozocin therapy in the preoperative treatment of localized pancreatic neuroendocrine tumors[J]. J Gastrointest Surg, 2017, 21(1):155-163.
[32]	Chua J, Nafziger E, Leung D. Evidence-based practice: temozolomide beyond glioblastoma[J]. Curr Oncol Rep, 2019, 21(4):30.
[33]	Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors[J]. Clin Cancer Res, 2007, 13(10):2986-2991.
[34]	Squires MH, Worth PJ, Konda B, et al. Neoadjuvant capecitabine/temozolomide for locally advanced or metastatic pancreatic neuroendocrine tumors[J]. Pancreas, 2020, 49(3):355-360.
[35]	Kunz PL, Graham NT, Catalano PJ, et al. Randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors (ECOG-ACRIN E2211)[J]. J Clin Oncol, 2023, 41(7):1359-1369.
[36]	Camus B, Cottereau AS, Palmieri LJ, et al. Indications of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic and pulmonary neuroendocrine tumors: an updated review[J]. J Clin Med, 2021, 10(6):1267.
[37]	Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors[J]. N Engl J Med, 2017, 376(2):125-135.
[38]	Schiavo Lena M, Partelli S, Castelli P, et al. Histopathological and immunophenotypic changes of pancreatic neuroendocrine tumors after neoadjuvant peptide receptor radionuclide therapy (PRRT)[J]. Endocr Pathol, 2020, 31(2):119-131.
[39]	高瑞泽, 孙文兵, 周意明, 等. 介入治疗神经内分泌肿瘤肝转移的进展[J]. 中华普通外科杂志, 2023, 38(3):234-237.

Please choose a citation manager

Content to export